Monday, January 30, 2012 4:00p.m. (Eastern):
Hologic Announces First Quarter Fiscal 2012 Operating Results
Read Release
Listen to Live Webcast
 View Presentation

Monday, January 9, 2012:
Hologic Announces Denial Of Conceptus' Request For Injunction In Patent Infringement Suit
Read Release

Thursday, December 15, 2011:
FDA Approves Hologic's Cervista High Throughput Automation System for Cervical Cancer Screening
Read Release

Thursday, December 1, 2011:
Hologic To Present At The NASDAQ OMX 27th Investor Program in London
Read Release
Listen to Webcast
 View Presentation

Tuesday, November 29, 2011:
Hologic To Host Investor Presentation At RSNA 2011
Read Release
Listen to Webcast
 View Presentation
Video: Clinicians Talk about Tomo

Welcome

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Headquartered in Bedford, Massachusetts, Hologic employs approximately 5,000 employees worldwide. The Company's Common Stock is listed on the Nasdaq Global Select Market under the trading symbol "HOLX".